Regulatory framework for compounded GLP-1 medications.
Updated June 1, 2026
Updated: June 1, 2026 · Editorial review: GLP-1 Price Guide Editorial Team · Pricing verified: June 1, 2026
Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
Important medical and regulatory disclosure
Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.
Frequently asked questions
What is the regulations section?
It is explanations of the FDA framework, 503B bulks proposal, and state rules. Every page is reviewed against our published pricing methodology.
How does GLP-1 Price Guide compare providers?
We score providers on true monthly cost, pharmacy transparency, provider oversight, shipping, dose policy, and marketing honesty — not the advertised starter price.
Why does true monthly cost matter more than the starter price?
Many programs advertise a low first-month price, then charge more at maintenance dose or add membership and shipping fees. True monthly cost reflects what you actually pay long term.
Are compounded GLP-1 medications FDA-approved?
Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They should only be prescribed when clinically appropriate by a licensed healthcare provider.
How often is pricing updated?
Pricing is re-verified monthly from publicly available provider pages and dated third-party sources, and labeled with a confidence status.